Publications & Presentations
Results from the Phase 1 Portion of a Phase 1/2 Study of the Irreversible PI-3K Inhibitor PX-866 and Docetaxel
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Nov. 13, 2011
Download Poster »  260 KB
Results from the Phase 1 Portion of a Phase 1/2 Study of the Irreversible PI-3K Inhibitor PX-866 and Cetuximab
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Nov. 13, 2011
Download Poster » 268 KB
PI3K inhibition combined with either cetuximab or docetaxel in a direct patient tumor model of HPV-positive and negative head and neck cancers
American Association for Cancer Research Annual Conference, April 3, 2011
Download Poster » 750 KB
17-hydroxy-PX-866, the primary metabolite of PX-866, an irreversible, pan-isoform inhibitor of phosphatidylinositol-3 (PI3) kinase, has increased activity in biochemical and cellular assays
American Association for Cancer Research (AACR) Special Conference "Targeting PI3K/mTOR Signaling," February 26, 2011
Download Poster » 816 KB
A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase
22nd EORTC/NCI/AACR Symposium on "Molecular Targets and Cancer Therapeutics," November 2011
Download Poster » 343 KB
Final Results from a Phase I Dose-Escalation Study of PX-866, an Irreversible, Pan-Isoform Inhibitor of PI3 Kinase
American Society of Clinical Oncology (ASCO) Annual Meeting, June 2010
Download Poster » 162 KB
Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor
American Society of Clinical Oncology (ASCO) Annual Meeting, June 2009
Download Poster » 208 KB
Inhibition of PI3K Prevents Transforming Growth Factor-alpha Induced Pulmonary Fibrosis
American Thoracic Society International Conference, May 2009
Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-?-Induced Pulmonary Fibrosis
Le Cras, et. al,
The Journal of Pathology, 2010 Feb;176(2):679-86
return to top ^
|
